These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24332870)

  • 1. Influence of combinations of drugs that act on the CYP2D6 metabolic pathway in the treatment of major depressive disorder: a population-based study.
    Sicras-Mainar A; Guijarro P; Armada B; Blanca-Tamayo M; Navarro-Artieda R
    Eur Psychiatry; 2014 Aug; 29(6):331-7. PubMed ID: 24332870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences.
    Sicras-Mainar A; Guijarro P; Armada B; Blanca-Tamayo M; Navarro-Artieda R
    PLoS One; 2014; 9(11):e90453. PubMed ID: 25369508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors.
    Gressier F; Verstuyft C; Hardy P; Becquemont L; Corruble E
    J Neural Transm (Vienna); 2015 Jan; 122(1):35-42. PubMed ID: 25047911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study.
    Dahl ML; Leander K; Vikström M; Frumerie C; Nordenmalm S; Möller J; Söderberg-Löfdal K
    Sci Rep; 2021 Mar; 11(1):5796. PubMed ID: 33707555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
    Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
    CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
    D'Empaire I; Guico-Pabia CJ; Preskorn SH
    J Psychiatr Pract; 2011 Sep; 17(5):330-9. PubMed ID: 21926528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients.
    Serretti A; Calati R; Massat I; Linotte S; Kasper S; Lecrubier Y; Sens-Espel R; Bollen J; Zohar J; Berlo J; Lienard P; De Ronchi D; Mendlewicz J; Souery D
    Int Clin Psychopharmacol; 2009 Sep; 24(5):250-6. PubMed ID: 19593158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study.
    Setiawan E; Attwells S; Wilson AA; Mizrahi R; Rusjan PM; Miler L; Xu C; Sharma S; Kish S; Houle S; Meyer JH
    Lancet Psychiatry; 2018 Apr; 5(4):339-347. PubMed ID: 29496589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions in the treatment of depression in patients receiving β-blocker drugs.
    Andrade C
    J Clin Psychiatry; 2013 Jan; 74(1):e75-8. PubMed ID: 23419233
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
    Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
    Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.
    Peñas-Lledó EM; Trejo HD; Dorado P; Ortega A; Jung H; Alonso E; Naranjo ME; López-López M; Llerena A
    Mol Psychiatry; 2013 Jan; 18(1):8-9. PubMed ID: 22733128
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
    Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
    Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
    Gedde-Dahl A; Spigset O; Molden E
    Eur J Clin Pharmacol; 2022 Oct; 78(10):1623-1632. PubMed ID: 35871665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with Newly Initiated Antidepressant Medication in Rhode Island Medicaid: Analysis and Insights for Promoting Patient Adherence.
    Kogut S; Quilliam BJ; Marcoux R; McQuade W; Wojciechowski C; Wentworth C; Plonsky R; Wood N
    R I Med J (2013); 2016 Apr; 99(4):28-32. PubMed ID: 27035137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
    Berm EJ; Hak E; Postma M; Boshuisen M; Breuning L; Brouwers JR; Dhondt T; Jansen PA; Kok RM; Maring JG; van Marum R; Mulder H; Voshaar RC; Risselada AJ; Venema H; Vleugel L; Wilffert B
    Trials; 2015 Jan; 16():37. PubMed ID: 25636328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders.
    Lee MS; Lee HY; Kang SG; Yang J; Ahn H; Rhee M; Ko YH; Joe SH; Jung IK; Kim SH
    J Affect Disord; 2010 Jun; 123(1-3):216-21. PubMed ID: 19914719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.